This molecule, belonging to the gp96 family, is the first heat shock protein identified
as a tumor rejection antigen.
Not exact matches
The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4
as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for
tumor rejection antigens, including the first
tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.
Pramod Srivastava and M.R. Das identify the gp100 molecule
as an individually specific
tumor rejection antigen of a rat hepatoma.
IDO1 has been implicated in immune modulation through its ability to limit T cell function and engage mechanisms of immune tolerance, and
as such preventing
tumor rejection.
Moreover, knock in animal models for syngeneic studies and allowing us to isolate transgenic armed effector cells are developed in order to show proof of concept for the diverse applicability of our modular targeting systems including for
tumor diseases, autoimmune diseases, GvHD, transplantation /
rejection as well
as viral infections.